Earnings Results, Esteemed Recognitions, and Conference Call Schedules - Analyst Notes on Covance, Alere, LabCorp, Charles River and WuXi PharmaTech

NEW YORK, May 8, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Covance Inc. (NYSE: CVD), Alere Inc. (NYSE: ALR), Laboratory Corp. of America Holdings (NYSE: LH), Charles River Laboratories International, Inc. (NYSE: CRL) and WuXi PharmaTech (Cayman) Inc. (NYSE: WX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2179-100free.

--
Covance Inc. Analyst Notes
On May 1, 2014, Covance Inc. (Covance) reported its Q1 2014 financial results with net revenue of $620.1 million, up 6.9% YoY. Net income totaled $50.8 million, up 5.5% YoY, while GAAP net earnings came in at $0.88 per diluted share, up 2.5% YoY. Commenting on the future outlook, Joe Herring, Chairman and CEO of Covance said, "Looking ahead, we expect increases of a few cents in earnings per share each quarter as we progress throughout the year. We are narrowing our 2014 financial expectations to revenue growth of 6% to 9% and pro forma diluted earnings per share of $3.70 to $3.95." The full analyst notes on Covance are available to download free of charge at:

http://www.analystsreview.com/2179-CVD-08May2014.pdf

--
Alere Inc. Analyst Notes
On April 29, 2014, Alere Inc. (Alere) reported its Q1 2014 financial results with net revenue of $716.6 million compared to $739.2 million in Q1 2013. Net loss attributable to common stockholders of Alere came in at $11.5 million, or $0.14 compared to net income attributable to common stockholders of $7.2 million, or $0.09 per common share in Q1 2013. Ron Zwanziger, Chairman, CEO and President of Alere commented, "Strong free cash flow generated during the quarter enable us to reduce our net debt to adjusted EBITDA ratio during the quarter, again demonstrating our commitment to delivering continuing shareholder value." The full analyst notes on Alere are available to download free of charge at:

http://www.analystsreview.com/2179-ALR-08May2014.pdf

--
Laboratory Corp. of America Holdings Analyst Notes
On May 5, 2014, Laboratory Corporation of America Holdings (LabCorp) announced the schedule of its Annual Meeting of Stockholders. The Company informed that the meeting will be webcast live beginning May 14, 2014 at 9:00 a.m. EDT through the Company's website. An archived replay of the audio webcast will also be available through June 13, 2014. The full analyst notes on LabCorp are available to download free of charge at:

http://www.analystsreview.com/2179-LH-08May2014.pdf

--
Charles River Laboratories International, Inc. Analyst Notes
On April 30, 2014, Charles River Laboratories International, Inc. (Charles River) reported its Q1 FY 2014 (period ended March 29, 2014) financial results with revenues of $299.4 million, up 2.8% YoY. GAAP net income from continuing operations came in at $32.6 million, or $0.67 per diluted share, compared to $25.9 million, or $0.53 per diluted share in Q1 FY 2013. "The first quarter operating results were in line with our expectations." said James C. Foster, Chairman, President and CEO. "We continued to make progress in the first quarter on our efficiency initiatives, as well as our strategy to expand our unique, early-stage portfolio through acquisitions." The Company anticipates 2014 net sales growth of 9% to 11% YoY; and GAAP EPS to be in the range of $2.64 to $2.74. The full analyst notes on Charles River are available to download free of charge at:

http://www.analystsreview.com/2179-CRL-08May2014.pdf

--
WuXi PharmaTech (Cayman) Inc. Analyst Notes
On May 1, 2014, WuXi PharmaTech (Cayman) Inc. (Wuxi) announced that it has been the recipient of the 2013 Lilly Global Supplier Award from Eli Lilly and Company (Lilly), marking the third time that WuXi has been honored with this award. According to the Company, the honor recognizes WuXi AppTec's contributions to Lilly's drug development programs. Dr. Ge Li, Chairman and CEO commented, "This award reflects our commitment to provide high-quality services to Lilly and to all of our 1,700 global customers. We continue our mission to build a broad, integrated platform of R&D services that enables anyone and any company to discover, develop and commercialize healthcare products to benefit patients globally." The full analyst notes on WuXi PharmaTech are available to download free of charge at:

http://www.analystsreview.com/2179-WX-08May2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED